Martin Lluesma Silvia, Wolfer Anita, Harari Alexandre, Kandalaft Lana E
Center of Experimental Therapeutics, Ludwig Center for Cancer Res, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland.
Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland.
Biomedicines. 2016 May 3;4(2):10. doi: 10.3390/biomedicines4020010.
Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the disease is usually diagnosed at an advanced stage, its prognosis remains very poor. Clearly, there is a critical need for new treatment options, and immunotherapy is one attractive alternative. Prophylactic vaccines for prevention of infectious diseases have led to major achievements, yet therapeutic cancer vaccines have shown consistently low efficacy in the past. However, as they are associated with minimal side effects or invasive procedures, efforts directed to improve their efficacy are being deployed, with Dendritic Cell (DC) vaccination strategies standing as one of the more promising options. On the other hand, recent advances in our understanding of immunological mechanisms have led to the development of successful strategies for the treatment of different cancers, such as immune checkpoint blockade strategies. Combining these strategies with DC vaccination approaches and introducing novel combinatorial designs must also be considered and evaluated. In this review, we will analyze past vaccination methods used in ovarian cancer, and we will provide different suggestions aiming to improve their efficacy in future trials.
上皮性卵巢癌（EOC）是妇科癌症相关死亡的一个重要原因。目前，卵巢癌治疗的主要手段包括减瘤手术和铂类化疗（30年前引入），但由于该疾病通常在晚期才被诊断出来，其预后仍然很差。显然，迫切需要新的治疗选择，免疫疗法是一个有吸引力的替代方案。预防传染病的预防性疫苗已经取得了重大成就，但治疗性癌症疫苗在过去一直显示出疗效低下。然而，由于它们的副作用或侵入性操作最小，人们正在努力提高其疗效，树突状细胞（DC）疫苗接种策略是更有前景的选择之一。另一方面，我们对免疫机制理解的最新进展导致了治疗不同癌症的成功策略的发展，如免疫检查点阻断策略。还必须考虑和评估将这些策略与DC疫苗接种方法相结合并引入新的组合设计。在这篇综述中，我们将分析过去用于卵巢癌的疫苗接种方法，并提供不同的建议，旨在提高其在未来试验中的疗效。
